MedTrace Logo

Manufacture of Clinical T-cell Products for Future Treatment

NCT05713513 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2023-02-06

No results posted yet for this study

Summary

The aim of this pilot study is to validate the manufacture of T-cell products using GMP-approved reagents for future clinical use. Lymphocytes from whole blood of max 300ml from volunteers or from total 9 volunteer apheresates will be isolated to validate the protocol under Good Manufacturing Practice (GMP).

Conditions

  • Virus-specific T Cells

Interventions

OTHER

Leukapheresis

Leukapheresis to isolate 1x10e9 cells, examined for purity and specificity under Good Manufacturing Practice (GMP)

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Nina Khanna, Prof. Dr. med. · University Hospital Basel, Departement Infektiologie & Spitalhygiene

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-24
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05713513 on ClinicalTrials.gov